Advertisement
UK markets close in 5 hours 38 minutes
  • FTSE 100

    8,148.62
    -15.05 (-0.18%)
     
  • FTSE 250

    20,150.80
    -45.15 (-0.22%)
     
  • AIM

    778.87
    -1.56 (-0.20%)
     
  • GBP/EUR

    1.1888
    +0.0009 (+0.07%)
     
  • GBP/USD

    1.2703
    -0.0058 (-0.46%)
     
  • Bitcoin GBP

    52,683.75
    -292.12 (-0.55%)
     
  • CMC Crypto 200

    1,425.88
    +8.01 (+0.56%)
     
  • S&P 500

    5,433.74
    +12.71 (+0.23%)
     
  • DOW

    38,647.10
    -65.11 (-0.17%)
     
  • CRUDE OIL

    78.46
    -0.16 (-0.20%)
     
  • GOLD FUTURES

    2,334.10
    +16.10 (+0.69%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • HANG SENG

    17,941.78
    -170.85 (-0.94%)
     
  • DAX

    18,099.87
    -165.81 (-0.91%)
     
  • CAC 40

    7,556.51
    -151.51 (-1.96%)
     

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT S.A.
GENFIT S.A.

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2022:

  • 138,691 shares

  • €534 070.18

During the second half of 2022, total trading was:

ADVERTISEMENT
  • On the buy side: 1339,376 shares for a total amount of €5,332,876.57

  • On the sell side: 1360,706 shares for a total amount of €5,417,420.02

During this same period, the number of trades were:

  • On the buy side: 2,627

  • On the sell side: 2,681

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

  • 27, 911 shares

  • €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.

Its R&D pipeline covers five therapeutic areas via six independent programs which explore the potential of differentiated mechanisms of action, across a variety of development stages (Phase 1, Phase 2, Phase 3). These diseases are acute on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorder (UCD)/organic acidemia disorder (OAD) and primary biliary cholangitis (PBC). Beyond therapeutics, GENFIT’s pipeline also includes a diagnostic franchise focused on NASH and ACLF.

GENFIT has facilities in Lille and Paris, France, Zurich, Switzerland, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT’s research and development programs. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations, potential synergies related to the acquisition of Versantis and our capacity to integrate its assets and develop its programs, and our continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2021 Universal Registration Document filed with the AMF on April 29 2022 under n° D.22-0400, which is available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022 and the 2022 Half-Year Business and Financial Report. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

  

APPENDIX
H2 2022

 

 

 

 

 

 

 

 

Buy side

Sell side

Date

Number of executions

Number of shares

Traded amounts in EUR

Number of executions

Number of shares

Traded amounts in EUR

TOTAL

2 627

1 339 376

5 332 876,57

2 681

1 360 706

5 417 420,02

01/07/2022

18

2832

8 636,41

13

2469

7 579,59

04/07/2022

15

2808

8 691,55

26

8288

25 737,37

05/07/2022

26

7955

25 355,01

29

20374

65 398,59

06/07/2022

16

4220

13 276,05

12

2554

8 074,20

07/07/2022

6

1292

4 214,35

24

8899

28 843,38

08/07/2022

2

353

1 147,97

3

353

1 155,01

11/07/2022

23

4786

16 105,83

60

12921

44 025,39

12/07/2022

94

20252

70 347,19

58

13230

46 243,87

13/07/2022

42

10361

35 632,51

75

14935

51 843,11

14/07/2022

51

7594

26 838,57

55

8492

30 277,12

15/07/2022

24

5592

20 168,69

27

6489

23 669,94

18/07/2022

9

1389

5 408,47

15

2212

8 634,27

19/07/2022

27

8839

34 172,53

38

13773

54 079,10

20/07/2022

24

7265

28 590,78

17

3085

12 212,57

21/07/2022

34

8808

34 820,54

41

11812

46 866,87

22/07/2022

32

22153

89 152,26

28

18909

76 315,28

25/07/2022

12

14922

59 574,53

19

13427

53 899,65

26/07/2022

31

11232

44 551,72

40

20028

80 002,82

27/07/2022

19

10060

41 342,68

39

26415

108 378,27

28/07/2022

26

9418

38 912,08

17

7242

30 148,74

29/07/2022

17

12497

51 651,92

20

7914

32 974,57

01/08/2022

1

1

4,10

3

1501

6 274,10

02/08/2022

9

6263

25 585,08

15

7001

28 751,16

03/08/2022

5

1001

4 190,16

8

6174

26 306,37

04/08/2022

1

1

4,30

10

2368

10 196,80

05/08/2022

1

1

4,21

1

1

4,21

08/08/2022

17

7348

32 226,71

44

17336

75 576,32

09/08/2022

34

20558

90 621,14

65

25540

113 134,55

10/08/2022

14

8158

36 494,73

17

11554

51 898,22

11/08/2022

14

7576

34 673,02

40

22251

102 215,38

12/08/2022

35

33277

155 164,19

22

13303

62 918,65

15/08/2022

5

2353

10 456,73

4

2353

10 602,56

16/08/2022

22

21578

95 969,67

16

7644

34 110,93

17/08/2022

22

22619

100 329,00

51

26105

116 296,45

18/08/2022

26

20650

91 952,66

39

20638

92 295,75

19/08/2022

13

5807

26 015,34

25

9945

44 599,92

22/08/2022

36

28559

126 375,37

43

19848

88 138,13

23/08/2022

10

16492

71 930,24

27

19189

84 180,80

24/08/2022

12

11909

52 188,66

27

17382

76 930,61

25/08/2022

31

10729

48 265,79

6

7628

34 572,63

26/08/2022

38

44327

192 992,68

34

16002

69 508,54

29/08/2022

12

13951

58 307,65

23

13951

58 628,41

30/08/2022

1

1

4,20

2

2693

11 590,57

31/08/2022

10

3515

14 902,59

1

1

4,24

01/09/2022

33

24865

102 788,38

5

2150

8 913,99

02/09/2022

7

4293

17 648,42

34

19333

80 084,35

05/09/2022

19

20428

82 590,12

6

3890

15 614,57

06/09/2022

18

24973

102 387,67

53

40867

167 645,46

07/09/2022

5

6561

26 954,80

29

25222

105 209,62

08/09/2022

43

31387

130 644,08

38

19826

82 034,71

09/09/2022

12

10404

44 324,93

24

22838

97 386,75

12/09/2022

18

12319

52 584,99

46

9844

42 208,64

13/09/2022

19

15108

65 074,08

30

17848

77 190,62

14/09/2022

14

7915

34 731,84

41

34226

153 756,47

15/09/2022

46

37477

157 799,25

15

7870

33 027,27

16/09/2022

38

19386

79 021,86

7

9608

39 669,71

19/09/2022

15

10082

41 220,27

36

22125

90 601,06

20/09/2022

27

15990

65 748,78

23

16552

68 650,63

21/09/2022

80

30448

122 056,66

15

10434

41 632,01

22/09/2022

54

32105

125 279,63

35

22489

87 974,88

23/09/2022

60

29919

114 633,69

16

12423

47 510,51

26/09/2022

51

13923

52 389,27

17

14149

53 597,74

27/09/2022

1

1

3,79

18

10784

41 364,22

28/09/2022

14

13249

49 988,03

26

16143

61 613,37

29/09/2022

17

17488

66 805,18

18

11149

42 489,89

30/09/2022

30

21589

80 660,81

30

20170

75 931,90

03/10/2022

25

11454

43 148,41

26

16250

61 858,59

04/10/2022

1

1

3,85

7

6532

25 796,50

05/10/2022

18

12767

49 687,55

1

1

4,00

06/10/2022

5

4844

18 736,65

10

7218

28 068,37

07/10/2022

13

8500

33 185,00

26

27500

107 755,09

10/10/2022

26

18069

69 895,02

18

8563

32 920,96

11/10/2022

25

5001

19 368,90

23

16007

62 603,86

12/10/2022

22

18812

74 025,73

5

1097

4 322,17

13/10/2022

20

8222

32 145,19

33

11629

45 869,37

14/10/2022

19

4723

19 220,49

16

9909

40 368,53

17/10/2022

17

3953

16 180,75

16

7571

31 231,06

18/10/2022

32

15666

64 248,53

11

5963

24 598,95

19/10/2022

30

18424

72 980,23

12

5078

20 011,61

20/10/2022

27

13956

53 614,74

27

10136

39 044,83

21/10/2022

31

6437

24 646,12

6

4061

15 629,64

24/10/2022

21

8927

34 293,22

26

10423

40 186,91

25/10/2022

6

5534

21 938,91

24

10985

43 633,67

26/10/2022

15

6559

26 531,41

14

6559

26 662,57

27/10/2022

25

9306

37 840,19

28

12558

51 282,53

28/10/2022

22

8654

34 898,81

6

3833

15 480,18

31/10/2022

8

5134

20 559,61

13

6708

27 035,49

01/11/2022

16

6687

26 819,27

8

2657

10 709,87

02/11/2022

16

9156

36 412,91

17

6373

25 412,77

03/11/2022

31

13140

51 341,18

4

1217

4 804,74

04/11/2022

16

8883

33 606,06

6

2694

10 288,20

07/11/2022

6

4274

16 123,65

19

9755

37 131,68

08/11/2022

22

9262

35 095,54

4

2670

10 107,16

09/11/2022

5

2707

10 244,60

2

2

7,59

10/11/2022

10

5406

20 415,75

16

7883

30 006,96

11/11/2022

32

11846

45 522,04

13

7410

28 538,92

14/11/2022

26

17701

68 097,67

12

32875

127 390,75

15/11/2022

8

4189

15 875,70

26

32539

123 603,57

16/11/2022

11

4883

18 515,64

3

1246

4 712,41

17/11/2022

14

6556

24 580,92

2

1181

4 407,54

18/11/2022

11

3634

13 447,77

10

21514

80 055,49

21/11/2022

9

3692

13 660,40

15

4494

16 689,22

22/11/2022

20

9455

34 165,67

14

5709

20 715,99

23/11/2022

8

1448

5 177,80

8

2543

9 154,80

24/11/2022

4

2088

7 550,53

10

3266

11 877,50

25/11/2022

8

2469

8 812,20

8

3414

12 265,45

28/11/2022

17

6652

23 726,33

12

4409

15 798,01

29/11/2022

29

8255

28 724,97

11

2460

8 542,89

30/11/2022

13

3523

12 079,07

8

3174

10 975,81

01/12/2022

26

4382

14 985,55

9

4288

14 728,95

02/12/2022

19

5893

19 979,66

13

7217

24 661,19

05/12/2022

24

8564

29 405,80

23

10534

36 427,04

06/12/2022

33

15052

50 880,54

7

2236

7 456,83

07/12/2022

14

6888

22 855,03

13

9278

30 970,32

08/12/2022

15

4492

14 844,38

9

4029

13 402,93

09/12/2022

19

8043

27 280,14

21

11612

39 335,34

12/12/2022

32

14821

49 336,65

26

6077

20 165,40

13/12/2022

14

5973

19 831,02

8

5186

17 330,36

14/12/2022

10

3008

10 003,81

5

2203

7 375,64

15/12/2022

15

6955

22 895,89

8

3478

11 511,50

16/12/2022

19

8737

28 556,32

13

5761

18 910,91

19/12/2022

5

1818

6 017,70

11

2741

9 105,47

20/12/2022

9

4328

14 206,66

10

5404

17 861,21

21/12/2022

9

3835

12 733,23

17

9080

30 470,95

22/12/2022

8

2851

10 016,56

28

8461

29 468,95

23/12/2022

12

4147

14 576,48

39

8935

31 654,68

27/12/2022

15

4797

17 336,21

12

7717

28 046,38

28/12/2022

15

7509

28 079,05

24

9089

33 821,51

29/12/2022

11

4830

18 456,14

38

13505

51 951,61

30/12/2022

25

10392

40 868,37

30

11640

45 997,31

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com     

Attachment